MedTrace Logo

GAD-M Regimen As First-Line Treatment in Untreated Extranodal NK/T Cell Lymphoma

NCT01991158 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2016-06-14

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of High dose of Methotrexate combined with gemcitabine, pegaspargase and dexamethasone (GAD-M regimen) as first-line treatment in patients with de novo extranodal NK/T cell lymphoma.

Conditions

  • Extranodal NK/T-cell Lymphoma, Nasal Type

Interventions

DRUG

High dose of methotrexate

Methotrexate 3.0g/Kg, intravenous drip D1

DRUG

Gemcitabine

Gemcitabine 1g/m2 intravenous drip D1,D8

DRUG

Pegaspargase

Pegaspargase 2500U/m2 intramuscular injection (IM) D1

DRUG

Dexamethasone

Dexamethasone 20mg/d intravenous drip D1, po D2-3

Sponsors & Collaborators

Principal Investigators

  • Wenqi Jiang, MD · Department of Medical Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, China State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center, Guangzhou, China

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-11-30
Primary Completion
2016-12-31
Completion
2020-11-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01991158 on ClinicalTrials.gov